James Healy Biography and Net Worth

Director of Rapport Therapeutics

Jim is the Managing Partner at Sofinnova Investments with over twenty three years of experience in funding innovative therapies. At Sofinnova, twenty two of his investments have gone public and twelve have been acquired. Prior to Sofinnova, Jim worked at Bayer and Sanderling. He received various recognitions over the course of his career including IBF Innovator, Xconomy’s Young and Proven Biotech VC’s and named one of Fortune’s Top Life Science Investors. An immunologist by training, Jim currently serves on the boards of ArriVent, Atsena, Bolt (BOLT), Karuna (KRTX), Natera (NTRA) and Y-mAbs (YMAB). He previously served on the boards of the Executive Committee at UC Berkeley, the National Venture Capital Association (NVCA) and the Biotechnology Innovation Organization (BIO). Jim received his M.D. and Ph.D. from Stanford University.

What is James Healy's net worth?: The estimated net worth of James Healy is at least $73.01 million as of October 28th, 2026. Dr. Healy owns 2,815,707 shares of Rapport Therapeutics stock worth more than $73,011,283 as of November 4th. This net worth estimate does not reflect any other investments that Dr. Healy may own. Learn More about James Healy's net worth.
How do I contact James Healy?: The corporate mailing address for Dr. Healy and other Rapport Therapeutics executives is 99 High Street, Suite 2100, Boston, MA, 02110. Rapport Therapeutics can also be reached via phone at (857) 321-8020 and via email at [email protected]. Learn More on James Healy's contact information.
Has James Healy been buying or selling shares of Rapport Therapeutics?: During the last quarter, James Healy has bought $20,359,080.00 in Rapport Therapeutics stock. Most recently, on Wednesday, October 28th, James Healy bought 969,480 shares of Rapport Therapeutics stock. The stock was acquired at an average cost of $21.00 per share, with a total value of $20,359,080.00. Following the completion of the transaction, the director now directly owns 2,815,707 shares of the company's stock, valued at $59,129,847. Learn More on James Healy's trading history.
Who are Rapport Therapeutics' active insiders?: Rapport Therapeutics' insider roster includes David Bredt (Insider), Abraham Ceesay (CEO), Cheryl Gault (COO), James Healy (Director), Troy Ignelzi (CFO), Krishnaswamy Yeleswaram (Insider), and Wendy Young (Director). Learn More on Rapport Therapeutics' active insiders.
Are insiders buying or selling shares of Rapport Therapeutics?: During the last year, Rapport Therapeutics insiders bought shares 7 times. They purchased a total of 1,031,174 shares worth more than $22,023,898.18. During the last year, insiders at the sold shares 36 times. They sold a total of 1,084,429 shares worth more than $42,882,750.72. The most recent insider tranaction occured on October, 28th when Director James Healy bought 969,480 shares worth more than $20,359,080.00. Insiders at Rapport Therapeutics own 12.5% of the company. Learn More about insider trades at Rapport Therapeutics.
Information on this page was last updated on 10/28/2026.

James Healy Insider Trading History at Rapport Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/28/2026	Buy	969,480	$21.00	$20,359,080.00	2,815,707
7/1/2024	Buy	44,032	$24.52	$1,079,664.64	40,851

James Healy Buying and Selling Activity at Rapport Therapeutics

Rapport Therapeutics Company Overview

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Today's Range

Now: $25.93

$25.27

$26.36

50 Day Range

MA: $35.26

$22.50

$52.50

2 Week Range

Now: $25.93

$22.06

$52.93

Volume

956,003 shs

Average Volume

1,474,196 shs

Market Capitalization

$1.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4